Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13D/A 0001918385 XXXXXXXX LIVE 3 Common Shares, par value (euro)0.12 per share 12/10/2025 false 0001809122 N2451R105 CureVac N.V. Friedrich-Miescher-Strasse 15 Tubingen 2M 72076 Brian S. North, Esquire (215) 665-8700 Buchanan Ingersoll & Rooney PC 50 South 16th Street, Suite 3200 Philadelphia PA 19102 Dr. Christina Eschenfelder 49 621 4256-275 RITTERSHAUS Harrlachweg 4 Mannheim 2M 68163 Y MH-LT-Investments GmbH a OO N 2M 0.00 0.00 0.00 0.00 0.00 N 0.00 OO 0001918385 N Dr. Matthias Hothum OO N 2M 0.00 0.00 0.00 0.00 0.00 N 0.00 IN Common Shares, par value (euro)0.12 per share CureVac N.V. Friedrich-Miescher-Strasse 15 Tubingen 2M 72076 This Amendment is being filed to reflect the completion of the Reporting Persons' exchange all of the Shares beneficially owned by them pursuant to an exchange offer (the "Exchange Offer") made by BioNTech SE, a European stock corporation ("BioNTech"). This Amendment is the final amendment to the Schedule 13D by the Reporting Persons and constitutes an "exit filing" by them. The Reporting Persons have tendered all of their Shares into the Exchange Offer. The Exchange Offer expired as scheduled at 9:00 a.m. Eastern Time on December 3, 2025. The Shares tendered by the Reporting Persons were accepted for exchange and transferred to BioNTech in a capital increase for the issue of shares in BioNTech underlying the American Depository Shares of BioNTech offered as consideration of the Exchange Offer which took effect upon registration on December 10, 2025. As a result, the Reporting Persons no longer beneficially own, or otherwise hold, any securities of the Issuer. The Reporting Persons expect to receive full consideration to which they are entitled under the Exchange Offer (the "Completion") on or about December 15, 2025. The information required by Items 5(a) and (b) is set forth in Rows 7 - 13 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. The Reporting Persons tendered all of their Shares in the Exchange Offer and, as a result of the issuance by BioNTech of its securities in the Exchange Offer on December 10, 2025, the Reporting Persons no longer beneficially own any Shares. The information required by Items 5(a) and (b) is set forth in Rows 7 - 13 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. Other than the transaction described in Item 5(a) no Reporting Person has effected any transaction in the Shares during the past sixty (60) days Not applicable. December 10, 2025. 99.1 Power of Attorney (Incorporated by reference to Exhibit 1 to Amendment No. 5 to Schedule 13D filed by the Reporting Persons with the SEC on May 5, 2022). 99.2 Joint Filing Agreement (Incorporated by reference to Exhibit 2 to Amendment No. 5 to Schedule 13D filed by the Reporting Persons with the SEC on May 5, 2022). MH-LT-Investments GmbH /s/ Dr. Christina Eschenfelder Dr. Christina Eschenfelder/Attorney-in-fact 12/12/2025 Dr. Matthias Hothum /s/ Dr. Christina Eschenfelder as attorney-in-fact MATTHIAS HOTHUM 12/12/2025